Capital CellCapital Cell is Europe’s first life sciences equity crowdfunding platform. Traditionally, life sciences investment has only been accessible to a small group of people with a high level of technical expertise and large sums to invest. Capital Cell opens life science investment to everyone by sourcing and screening the most innovative early-stage life science companies, and presenting them to the crowd through a regulated online investment platform. Capital Cell finances companies whose technology is based on biology or healthcare, and uses the crowdsourced expertise of the BioExpert Network to filter the companies being analysed. Capital Cell redefines life science investment, and through supporting scientific innovation, funds projects that change lives.
|Investor Type||Crowdfund and Online Investment Platforms|
|Services Provided||Live Pitch Presentations, Online Showcase|
|Investment Stage||Seed, Start-Up, Early Stage VC|
|Regions Covered||National, Continental Europe|
|Investment Range||Less than £150k, £150k - £250k, £250k - £500k, £500k - £1m, £1m - £3m|
|Sectors Considered||Healthcare, Med Tech and Digital Health, Life Sciences|
|Company Success Fee||Capital Cell charges a success fee of 5-7.5% (depending on the amount of capital raised). We also charge a listing fee of £750, but the company analysis and BioExpert Network Fast Market Feedback report is free of charge.|
Women take the lead in new model of biotech financing
This month has seen the launch of the first UK campaign on the equity crowdfunding platform...
Life sciences crowdfunding platform Capital Cell launches first UK campaign
Capital Cell, the first pan-European equity crowdfunding platform dedicated to life sciences, has announced the launch...
Equity crowdfunding on the agenda at two big events in London
In the coming weeks, Capital Cell will be leading discussions about the growing interest in equity...